The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine

Research output: Contribution to journalReviewResearchpeer-review


The concept of personalized medicine has predominantly been pursued through genomic and transcriptomic technologies, leading to the identification of multiple mutations in a large variety of cancers. However, it has proven challenging to distinguish driver and passenger mutations and to deal with tumor heterogeneity and resistant clonal populations. More generally, these heterogeneous mutation patterns do not in themselves predict the tumor phenotype. Analysis of the expressed proteins in a tumor and their modification states reveals if and how these mutations are translated to the functional level. It is already known that proteomic changes including posttranslational modifications are crucial drivers of oncogenesis, but proteomics technology has only recently become comparable in depth and accuracy to RNAseq. These advances also allow the rapid and highly sensitive analysis of formalin-fixed and paraffin-embedded biobank tissues, on both the proteome and phosphoproteome levels. In this perspective, we highlight pioneering mass spectrometry-based proteomic studies that pave the way towards clinical implementation. We argue that proteomics and phosphoproteomics could provide the missing link to make omics analysis actionable in the clinic. This article is protected by copyright. All rights reserved.

Original languageEnglish
Article numbere1800113
JournalProteomics - Clinical Applications
Issue number2
Number of pages10
Publication statusPublished - 2019

Bibliographical note

Special Issue: Clinical Proteomics on the Way Towards Implementation

Number of downloads are based on statistics from Google Scholar and

No data available

ID: 214023271